Tag: WVE007
-
Wave Life Sciences Reports Promising Phase 1 Results for WVE-007: Significant Body Composition Improvement in Obesity Patients
Wave Life Sciences USA, Inc. Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically…
-
Wave Life Sciences to Reveal Interim Data from Phase 1 INLIGHT Trial of WVE-007 for Obesity on December 8, 2025
Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using…